Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Chief Financial Officer | November 10, 2022 | November 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mirum Pharmaceuticals, Inc.
Report date November 10, 2022 · Filed November 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,011 |
Reported balance
After 2022-11-10 transaction · row 1
1 source rowRow 1 · 2022-11-10 · Grant · Acquired 325 · Balance 30,011 F1: This Form 4 is being filed voluntarily to report the acquisition of 325 shares by the Reporting Person on November 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed voluntarily to report the acquisition of 325 shares by the Reporting Person on November 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2022 Filed Nov 14, 2022 21:46 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 325 | $17.05 | $5,541.58 |
DisclosureSEC source: 0001209191-22-056891 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,011 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 325 shares by the Reporting Person on November 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 10, 2022 Filed May 12, 2022 21:14 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,125 | $13.57 | $15,261.75 |
DisclosureSEC source: 0001209191-22-028719 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,686 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,125 shares by the Reporting Person on May 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 16:52 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001209191-22-002426 · doc4.xml · derivative · entry 2 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-05 F2 · derivative.exercise_date: 1/4th of the shares vest one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 16:52 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002426 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,561 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:49 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 750 | $13.90 | $10,425.00 |
DisclosureSEC source: 0001209191-21-067068 · doc4.xml · nonDerivative · entry 2 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,561 F1 · kind: The Reporting Person's purchases of MIRM common stock reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of 1,574 shares of MIRM common stock on October 1, 2021 at a price of $19.256. The transactions resulted in short-swing profits of $7,416.20 which the Reporting Person has disgorged to MIRM in accordance with Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| November 24, 2021 Filed Nov 29, 2021 21:49 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 700 | $14.40 | $10,080.00 |
DisclosureSEC source: 0001209191-21-067068 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,811 F1 · kind: The Reporting Person's purchases of MIRM common stock reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the Reporting Person's sale of 1,574 shares of MIRM common stock on October 1, 2021 at a price of $19.256. The transactions resulted in short-swing profits of $7,416.20 which the Reporting Person has disgorged to MIRM in accordance with Section 16(b) of the Securities Exchange Act of 1934. Read SEC document |
| November 10, 2021 Filed Nov 15, 2021 16:16 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 458 | $13.52 | $6,189.87 |
DisclosureSEC source: 0001209191-21-064447 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,111 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 458 shares by the Reporting Person on November 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 01, 2021 Filed Oct 1, 2021 20:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,574 | $19.26 | $30,308.94 |
DisclosureSEC source: 0001209191-21-058607 · doc4.xml · nonDerivative · entry 2 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,653 F2 · shares: Shares sold to cover tax withholding obligations associated with the vesting of the performance-based restricted stock unit award granted to the Reporting Person on March 9, 2021. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:00 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 9,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-058607 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,227 F1 · shares: The shares became issuable upon the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of a performance-based restricted stock unit award on March 9, 2021. On September 29, 2021, the Compensation Committee certified the achievement of the performance criteria resulting in the vesting of 4,687 shares on September 29, 2021 and 4,688 shares on June 30, 2023. Read SEC document |
| May 10, 2021 Filed May 12, 2021 17:27 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 981 | $14.62 | $14,342.22 |
DisclosureSEC source: 0001209191-21-032139 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,852 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 981 shares by the Reporting Person on May 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 17:32 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001209191-21-003022 · doc4.xml · derivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-06 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:12 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 1,562 | $18.65 | $29,131.30 |
DisclosureSEC source: 0001209191-20-065167 · doc4.xml · nonDerivative · entry 2 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,841 Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 16:12 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 908 | $18.55 | $16,843.40 |
DisclosureSEC source: 0001209191-20-065167 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,279 Read SEC document |
| December 23, 2020 Filed Mar 8, 2021 19:42 UTC Amendment | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 1,592 | $18.65 | $29,690.80 |
DisclosureSEC source: 0001209191-21-018770 · doc4a.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,871 F1 · shares: This Form 4 is being amended to correct the number of shares purchased and the amount of securities beneficially owned following the reported transaction. F1 · balance_after: This Form 4 is being amended to correct the number of shares purchased and the amount of securities beneficially owned following the reported transaction. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 17:06 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 1,371 | $15.27 | $20,929.69 |
DisclosureSEC source: 0001209191-20-058035 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,371 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,371 shares by the Reporting Person on November 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 17:35 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.24 | $0.00 |
DisclosureSEC source: 0001209191-20-003338 · doc4.xml · derivative · entry 1 Clements Ian · CIK 0001780080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 10, 2020 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 19:19 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 2,199 | $11.87 | $26,102.13 |
DisclosureSEC source: 0001209191-19-049092 · doc4.xml · nonDerivative · entry 2 Clements Ian · CIK 0001780080 · SVP Finance & Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F2 · price: The weighted average purchase price for the transaction reported was $11.87, and the range of prices were between $11.77 and $11.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 19:19 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | PurchaseCommon Stock | 1,801 | $11.07 | $19,937.07 |
DisclosureSEC source: 0001209191-19-049092 · doc4.xml · nonDerivative · entry 1 Clements Ian · CIK 0001780080 · SVP Finance & Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,801 F1 · price: The weighted average purchase price for the transaction reported was $11.07, and the range of prices were between $10.70 and $11.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.